



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 35/12, 31/685, 31/20		A1	(11) International Publication Number: WO 87/ 02247 (43) International Publication Date: 23 April 1987 (23.04.87)
(21) International Application Number: PCT/US86/02066 (22) International Filing Date: 2 October 1986 (02.10.86) (31) Priority Application Number: 787,741 (32) Priority Date: 15 October 1985 (15.10.85) (33) Priority Country: US (71) Applicant: BAXTER TRAVENOL LABORATORIES, INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). (72) Inventors: WARD, Michael, V. ; 427 W. Stratford Court, McHenry, IL 60050 (US); COTTER, Richard ; 188 Acorn Lane, Libertyville, IL 60048 (US). (74) Agents: FATO, Gildo, E. et al.; One Baxter Parkway, Deerfield, IL 60015 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published With international search report.	
(54) Title: RAPID ACTING INTRAVENOUS EMULSIONS OF OMEGA-3 FATTY ACID ESTERS			
(57) Abstract Lipid emulsions of marine oils comprising high concentrations of omega-3-fatty acid esters and low concentrations of free fatty acids for intravenous administration for the treatment of thrombotic disease states. More specifically, a lipid emulsion for parenteral use is provided comprising an emulsifier, water, and a marine oil comprising an omega-3 fatty acid ester, in which the concentration of free fatty acid in the emulsion is below about 5 meq/l.			

BEST AVAILABLE COPY

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 35/12, 31/685, 31/20		(11) International Publication Number: WO 87/02247	
		(43) International Publication Date: 23 April 1987 (23.04.87)	
(21) International Application Number: PCT/US86/02066		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(22) International Filing Date: 2 October 1986 (02.10.86)		Published with international search report.	
(31) Priority Application Number: 757,741			
(32) Priority Date: 15 October 1955 (15.10.55)			
(33) Priority Country: US			
(71) Applicant: BAXTER TRAVENOL LABORATORIES, INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US).			
(72) Inventors: WARD, Michael, V.; 427 W. Stratford Court, McHenry, IL 60050 (US); COYNE, Richard; 188 Acorn Lane, Libertyville, IL 60048 (US).			
(74) Agents: FATO, Guido, E. et al.; One Baxter Parkway, Deerfield, IL 60015 (US).			

(54) Title: RAPID ACTING INTRAVENOUS EMULSIONS OF OMEGA-3 FATTY ACID ESTERS

(57) Abstract

Lipid emulsions of marine oils comprising high concentrations of omega-3 fatty acid esters and low concentrations of free fatty acids for intravenous administration for the treatment of thrombotic diseases. More specifically, a lipid emulsion for parenteral use is provided comprising an emulsifier, water, and a mixture comprising an omega-3 fatty acid ester, in which the concentration of free fatty acid in the emulsion is below about 5 mg/dl.

FOR THE PURPOSES OF INFORMATION ONLY


Classified by: Family State: published by: In the form of: published by: International Patent Classification

AT	Austria	DE	Germany	MT	Malta
BE	Belgium	DK	Denmark	NI	Nicaragua
BR	Brazil	EE	Estonia	NO	Norway
CA	Canada	FI	Finland	PL	Poland
CH	Switzerland	FR	France	PT	Portugal
CY	Cyprus	GB	Great Britain	RO	Romania
CZ	Czech Republic	GR	Greece	RU	Russia
EE	Estonia	HN	Honduras	SK	Slovakia
ES	Spain	IE	Ireland	SN	Senegal
FI	Finland	IL	Israel	SO	Sierra Leone
FR	France	IN	India	TD	Chad
GB	Great Britain	IR	Iran	UG	Uganda
GE	Georgia	IS	Iceland	US	United States of America
GR	Greece	LU	Luxembourg		
GT	Guatemala	MG	Madagascar		
HN	Honduras				
IE	Ireland				
IL	Israel				
IN	India				
IR	Iran				
IS	Iceland				
IT	Italy				
JP	Japan				
KE	Kenya				
KH	Kampuchea				
KR	Korea				
LA	Laos				
LB	Lebanon				
LC	Liechtenstein				
LI	Liechtenstein				
LK	Sri Lanka				
LU	Luxembourg				
LV	Latvia				
LY	Libya				
MA	Morocco				
MC	Monaco				
MD	Moldavia				
ME	Montenegro				
MG	Madagascar				
MH	Marshall Islands				
ML	Mali				
MM	Myanmar				
MN	Mongolia				
MO	Macao				
MP	Marshall Islands				
MQ	Martinique				
MR	Morocco				
MS	Montserrat				
MT	Malta				
MU	Mauritius				
MV	Maldives				
MW	Malawi				
MX	Mexico				
MY	Malaysia				
MZ	Mozambique				
NA	Namibia				
NC	New Caledonia				
NE	Niger				
NG	Nigeria				
NH	Norfolk Island				
NI	Nicaragua				
NL	Netherlands				
NO	Norway				
NP	Nepal				
NR	Nauru				
NU	Niue				
NZ	New Zealand				
OM	Oman				
PA	Panama				
PE	Peru				
PF	French Polynesia				
PG	Papua New Guinea				
PH	Philippines				
PK	Pakistan				
PL	Poland				
PM	St. Pierre and Miquelon				
PN	Pitcairn Islands				
PR	Puerto Rico				
PS	Palestine				
PT	Portugal				
PW	Papua New Guinea				
PY	Paraguay				
QA	Qatar				
RE	Reunion				
RO	Romania				
RU	Russia				
SA	Saudi Arabia				
SB	Solomon Islands				
SC	Seychelles				
SD	Sudan				
SE	Sweden				
SG	Singapore				
SI	Slovenia				
SK	Slovakia				
SL	Sierra Leone				
SM	San Marino				
SN	Senegal				
SO	Sierra Leone				
SR	Suriname				
SS	South Sudan				
ST	San Tomé and Príncipe				
SV	El Salvador				
SY	Syria				
SZ	Swaziland				
TD	Chad				
TE	Togo				
TF	French Southern Territories				
TG	Togo				
TH	Thailand				
TJ	Tajikistan				
TK	Tokelau				
TL	Timor-Leste				
TM	Turkmenistan				
TN	Tunisia				
TO	Tonga				
TR	Turkey				
TT	Trinidad and Tobago				
TU	Turkmenistan				
TV	Tuvalu				
TW	Taiwan				
TZ	Tanzania				
UA	Ukraine				
UG	Uganda				
UK	United Kingdom				
US	United States of America				
UY	Uruguay				
UZ	Uzbekistan				
VA	Vatican City				
VC	St. Vincent and the Grenadines				
VE	Venezuela				
VG	British Virgin Islands				
VI	US Virgin Islands				
VN	Vietnam				
VU	Vanuatu				
WF	French Polynesia				
WS	Samoa				
YE	Yemen				
YT	Mayotte				
ZA	South Africa				
ZD	Zimbabwe				
ZM	Zambia				
ZW	Zimbabwe				

including soybean phosphatides, sorbitan monolaurate, polyglycerol esters of fatty acids, gelatin, cholesterol, sodium cholate and egg yolk phosphatides which are necessary to allow solubility of these lipids in an aqueous environment such as the blood stream were employed. (Thompson, S.M. The Pathology of Parenteral

Yang, P.C. and Wilmore, D.W., ed. Chicago, American Medical Association, 1970) This emulsion then established lipid emulsions as a viable nutrient therapy, and several emulsions of this composition are presently on the market. Recent additions to this family of lipid calorie sources are compositions of safflower oil and mixtures of cotton and safflower oils which appear to be

these lipids in an aqueous environment such as the blood stream were employed. (Thompson, S.W. The Pathology of Parenteral Nutrition with Lipids. Springfield, IL: Charles C. Thomas, 1974) This search was at first unsuccessful due to impurities



composition are presently on the market. Recent additions to this family of lipid calorie sources are compositions of safflower oil and mixtures of soybean and safflower oils which appear to be viable emulsions as well. (Ament, H.E., R.A. Cammen, and W.J.

-2-

such as high free fatty acids found in these primitive oils and emulsifiers. Over the last thirty years this search has focused on two possible oils and emulsifiers that showed therapeutic potential. The first of these were liquid emulsions composed of cottonseed oil (10 to 20% w/v), soybean phospholipid (1-5% w/v) and glycerin (2.25% w/v). Early emulsions of this composition showed a high degree of toxicity in both animals and man. (Meng, H.C. and J.S. Kaley, Effects of Multiple Infusions of a Fat Emulsion on Blood Coagulation, Liver Function, and Urinary Excretion of Steroids in Schizophrenic Patients. J Clin Nutr 16: 196-199, 1963) Since then such emulsions have undergone improvements. Both the oil and emulsifiers have been further characterized and purified and presently appear to provide a therapeutic capability to supply calories to the critically ill. (Lipofundin, a Fat Emulsion for Parenteral Hyperalimentation and Supply of Essential Fatty Acids, Germany: B. Braun, 1981) However, due to their notorious past, emulsions of such composition are little used in clinical nutrition.

The second emulsion which evolved during this period was one composed of purified soybean oil (10-20% w/v), egg yolk phospholipids (1-5% w/v) and 2.25% w/v glycerin. This emulsion, due to the purified nature of its components, produced clinically acceptable results as a calorie source in clinical nutrition. (Parentlind, A. Current Status of Intralipid and Other Fat Emulsions. pp109-122 in: Fat Emulsions in Parenteral Nutrition. Meng, H.C. and Wilmore, D.W., ed. Chicago, American Medical Association, 1976) This emulsion then established lipid emulsions as a viable nutrition therapy, and several emulsions of this composition are presently on the market. Recent additions to this family of lipid calorie sources are compositions of safflower oil and mixtures of soybean and safflower oils which appear to be viable emulsions as well. (Ament, H.C., R.A. Cammen, and W.D.

-1-

RAPID ACTING INTRAVENOUS EMULSIONS OF OMEGA-3 FATTY ACID ESTERS

BACKGROUND OF INVENTION

This invention relates to a therapeutic composition, methods for its preparation and for its use. More particularly, this invention relates to an emulsion of marine oil for treatment of thrombotic disease.

The therapeutic use of intravenous (IV) lipid emulsions in the clinically ill has its origin in antiquity. Physicians originally attempted infusions of olive oil and milk into the blood stream of critically ill patients in the 1600s and 1700s. The therapeutic reason for these infusions was to prevent starvation, often the deciding factor in the survival of such patients. Lipid is an attractive nutritional high calorie source (9kcal/g) as compared to carbohydrate (4kcal/g). These early experiments were unsuccessful due to severe adverse reactions. A long search for an appropriate lipid source for clinical nutrition ensued.

Various oil sources including butter oil, coconut oil, cottonseed oil, lard oil, olive oil, sesame seed oil, safflower oil and soybean oil, containing esters of fatty acids (6-22 carbons long) were tried. Also various emulsifying agents including soybean phosphatides, sorbitan monolaurate, polyglycerol esters of fatty acids, gelatin, cholesterol, sodium cholate and egg yolk phosphatides which are necessary to allow solubility of these lipids in an aqueous environment such as the blood stream were employed. (Thompson, S.W. The Pathology of Parenteral Nutrition with Lipids. Springfield, IL: Charles C. Thomas, 1974) This search was at first unsuccessful due to impurities

Byrne. Use of Intravenous Safflower Oil Emulsion (Liposyn 10%) as an Energy Source in Pediatric Patients on TPN. (p165 in Parenteral Nutrition in the Infant Patient. North Chicago, IL: Abbott Laboratories, 1983)) From this historical summary it would appear that the nature of the oil and emulsifier appear to be less important than their purity for their use in clinical nutritions.

As the emulsions were developed, the biochemistry of lipids was also evolving. This resulted in the discovery of the biological essentiality of certain polyunsaturated fatty acids [linoleic acid (C18:2 omega 6), arachidonic acid (C20:4 omega 6)]. (Holman, R.T. How Essential are Essential Fatty Acids. J Amer Oil Chem Soc, 55: 744A-741A, 1978) It was observed that lack of these essential fatty acids produced a clinical syndrome characterized by scaliness and lesions of skin, cessation of growth, renal degeneration, structural and metabolic changes in the central nervous system, increased metabolic rate, weight loss and finally death. (Caldwell, H.D. Human Essential Fatty Acid Deficiency: A Review in Fat Emulsions in Parenteral Nutrition. Heng, H.C. and Wilmore, D.W., eds. Chicago, IL: Amer Med Assoc, 1978) More recently, the essentiality of linolenic acid (C18:3 omega 3) has been postulated. Deficiencies in this fatty acid cause optical and neurological disturbances. (Heurfinger, H., W.E. Connor, C. Van Patten, and L. Bostad. Dietary Omega 3 Fatty Acid Deficiency and Visual Loss in Infant Rhesus Monkeys. J Clin Chem 73: 272-276, 1984) These developments further increased the therapeutic utility of lipids in clinical nutrition.

The fat emulsions outlined above have been used successfully both as a calorie and an essential fatty acid source for the last twenty years. (Pelham, D. Rational Use of Fat Emulsions. The Hosp Pharm Forum 10:1, 1981) Problems associated with their use are generally considered to be due to lipid overload. This is when concentrations of lipid in the emulsion or its metabolic

products (free fatty acids) are such that the body is unable to metabolize them. (Alexander, C.S. Fat infusions: Toxic Effects and Alterations in Fasting Serum Lipids Following Prolonged Use. Arch Intern Med 107: 94-94, 1961) This results in lipid accumulation in various cells, tissues, and organs of the body. (Udell, H.P., B.A. Bivins, J.Z. Jona, V.L. Young. Fat Overload with a 10% Soybean Oil Emulsion. Arch Surg 111: 1391, 1976) High levels in the blood of the emulsion's by-products, free fatty acids, have been shown to cause both cardiac and lung damage.

(Solair, L.A. Arrhythmias Following Infusions of Fatty Acids. Amer Heart J 63: 671, 1970; Bree, P.J., T.J.K. Young, S. Margolis, S. Permutt and J.L. Cameron. Pulmonary Injury Caused by Free Fatty Acids. Evaluation of steroid and albumin therapy. Surgery 90: 224, 1980)

Fat emulsions are recommended clinically to be used at dosages of 2.5 g/kg/day for adults and up to 4g/kg/24 hours for children. (Liposyn 10% 10% i.v. fat emulsion product insert.

Deerfield, IL: Traveler Laboratories, 1985) These emulsions contain no more than 5 meq/liter of free fatty acids. The dosage level of these emulsions are recommendations and each patient must be monitored for the build up of emulsions and free fatty acids during infusion to assure safety of such therapies. Extensive studies to assess the metabolism and pharmacokinetics of these emulsions during infusion have been conducted and are well understood at this time. (Gatter, P., L. Partis, F. Gorman, H.

Gargant, C. Taylor, W. Reas, L. Young, W. Reas, and L. Young. Nonlinear kinetic analysis of the elimination of lipid emulsion administered intravenously to adult patients. J Pharm Intake 17(3): 244-250, 1982)

(Gatter, P., L. Partis, F. Gorman, H. Gargant, C. Taylor, W. Reas, L. Young, W. Reas, and L. Young. Elimination and Pharmacokinetics of Lipid Emulsion in Adult Patients. Lipid Emulsion in the 1980s. J Pharm Intake 17(3): 149-155, 1982)

Cotter, R. L. Martis, F. Cosmas, C. Taylor, S. Young, W.B. Rowe, and R. Johnson. Comparison of the Elimination of 10 and 20% TRAVAMULSION Lipid Emulsion from the Blood of Beagle Dogs. *Amer J. Clin Nutr* 41(5): 994-1001, 1985)

- 5 Presently a new generation of lipid emulsions is under development. These emulsions are designed as therapeutic modalities for clinical conditions that have high metabolic energy requirements. These conditions are a result of hormonal and biochemical aberrations that alter normal energy metabolism and shift it into a hypermetabolic state. (Raymond, R., R. Cotter, F. Cosmas, and D. Gibbons. Development of a Chronic Peritoneal Abscess Model in the Dog from Evaluation of Clinical Therapies. *Fed Proc* 43: 325, 1984) Such states are found in critically ill patients suffering from trauma, sepsis and burns. (Kinney, J.H. and P. Felig. The Metabolic Response to Injury and Infection. *Endocrinology* 3: 1963, 1979) These emulsions are composed of medium chain fatty acids (C6 to C12) esterified to glycerol to form medium chain triglycerides which are emulsified with (1-5% wt/v) egg yolk phospholipids to give a final triglyceride concentration of 10 to 20% w/v. (Cotter, R., F. Cosmas, R. Johnson, W. Rowe, and L. Lin. A Comparison of the Elimination of Four Different Formulations of Parenteral Lipid Emulsions from the Blood Streams of the Beagle Dog. *Fed Proc* 44: 1156, 1985) These emulsions are of benefit in the hypermetabolic state as they supply twice as much metabolic energy per gram of lipid at a faster rate due to their unique biochemical advantage of carnitine independence, rapid betaoxidation and lack of deposition in organs and adipose tissue as compared to long chain triglycerides (C12-C24). (Cotter, R.C. Johnson, C.A. Taylor, T. Pavline, F. Cosmas, and W.B. Rowe. Metabolic Comparison of a 20% Combination Long and Medium Chain Triglyceride Lipid Emulsion and a 20% Long Chain Emulsion. *Fed Proc* 43: 848, 1984; Johnson, R.C., S.K.

Young, R. Cotter, and W.B. Rowe. Metabolism and Distribution of Medium Chain Triglyceride Lipid Emulsion. *Amer J. Clin Nutr* 41: 846, 1985) Extensive research has been carried out to develop and characterize these emulsions, illustrating their metabolic advantage. (Young, S.K., W.C. Johnson, R. Cotter, and W. Rowe. Competitive Interaction between Medium and Long Chain Lipid Emulsions. *Fed Proc* 43: 865, 1984).

- 10 The rapid bioavailability of lipid emulsions creates immediate biological effects and makes them attractive vehicles for acute intravenous therapies. Further studies have also shown that by reducing the phospholipid composition of the emulsion to about 0.4-0.6 of a more rapid bioavailability is produced. This rapid bioavailability is produced by creating a more attractive lipid particle for cellular uptake. Such apolipoproteins are essential for control of lipid metabolism and endothelial receptor binding and circulation of lipoproteins at these receptor sites. The reduction in phospholipids in such emulsions results in a more rapid delivery of the emulsion to metabolism and a release of the biologically active metabolic products. This brings about a rapid biological response to these therapies.
- 15 Lipid emulsions containing marine oil have been prepared for the treatment of disorders associated with deficiencies of arachidonic acid metabolites. Examples include: infantile scurvy; acute and chronic inflammatory diseases such as arthritis; and acute respiratory distress syndrome (ARDS), atherosclerosis, stroke, myocardial infarction, deep vein thrombosis and other cardiovascular diseases. The most notable cardiovascular risk factors include surgery, hyperlipidemic states, hypertension (stroke), enhanced platelet responsiveness, vascular lesions and occlusions, vascular spasm and distalities. Studies have shown that populations (concentric hypertensives) whose diets are rich in

marine products are at considerably reduced risk of developing coronary heart disease. (Editorial). Eskimo diets and diseases. Lancet: 1139-1141, May 21, 1983) Such diets are rich in fatty acids of the omega three (omega 3) family. The three members of this family which appear to play a significant role in this effect are linolenic acid (C18:3), eicosapentaenoic acid or EPA (C20:5), and docosahexaenoic acid or DHA (C22:6). (Bang, H.O., J. Dyerberg, and M. Hjorne. The Composition of Food Consumed by Greenland Eskimos. Acta Med Scand 200: 69-73, 1976)

In the average European and North American diet, linoleic acid (C18:2), an omega 6 fatty acid, is the predominantly consumed essential fatty acid, accompanied by low levels of linolenic acid. Linoleic acid is converted to arachidonic acid (C20:4), both of which are incorporated into the lipid component of cell membranes and serum, and give rise to metabolites of the omega 6 pathways.

Cold water marine animals contain low concentrations of the essential fatty acid, linolenic, in their tissues and large amount of two other members of the omega 3 family: EPA and DHA. These fatty acids are also incorporated into cell membranes and serum and give rise to metabolites of the omega 3 pathways. The two metabolic pathways containing the omega 3 fatty acids are not interchangeable in animals. However, the enzymes which metabolize the omega 6 and omega 3 series seem to be identical.

Most animal cells utilize these fatty acids to form various prostaglandins and leukotrienes. (Spector, A.A., T.L. Kudo, P.H. Flgard, K.C. Norton, J.C. Hoak, and R.L. Czerwik).

Eicosapentaenoic Acid and Prostacyclin Production by Cultured Human Endothelial Cells. J Lipid Res 24: 1595-1604, 1983; Lee, T.H., R.L. Hoover, J.D. Williams, et al. Effect of Dietary Enrichment with Eicosapentaenoic and Docosahexaenoic Acids on In Vitro Neutrophil and Monocyte Leukotriene Generation and

Neutrophil Function. N Engl J Med 312(19): 1217-1224, May 9, 1985) When fatty acids are released from cell membranes and intracellular pools, the lipoygenase and cyclooxygenase enzymes mediate the production of various eicosanoids. Although EPA is a relatively poor substrate for cyclooxygenase, it appears to have a high binding affinity and thereby inhibits arachidonic acid conversion by this enzyme. (Meddeman, P., A. Raz, M. Minkes, J.A. Ferrandelli, and H. Sprecher. Triene Prostaglandins, Prostacyclin and Thromboxane Biosynthesis and Unique Biological Properties. Proc Nat Acad Sci USA 76: 940, 1979) On the other hand, EPA is a good substrate for the lipoygenase enzymes. (Terano, T., J.A. Salmon, and S. Moncada. Biosynthesis and biological activity of leukotriene P₂. Prostaglandins 27(2): 217-232, 1984) In either case, EPA would have clinical application in disorders associated with elevated levels of arachidonic acid metabolites (examples: thromboxane mediated myocardial infarction; (Hay, C.R.H., A.P. Durbin, and P. Saynor. Effect of Fish Oil on Platelet Kinetics in Patients with Ischemic Heart Disease. Lancet 1269-1272, June 5, 1982) and leukotrienes in psoriasis. (Drain, S.D., R.D.R. Camp, A. Kobza Black, et al. Leukotrienes C₄ and D₄ in psoriatic skin lesions. Prostaglandins 29(4): 611-619, 1987)

An additional application of the omega 3 fatty acid pathway lies in the physiological activities of their cellular products. EPA has been shown to lower platelet activity. (Hilme, S., J.H. Gross, H. Crane, and A. Morley. The Effect of Albumin Bound Polyunsaturated Fatty Acids on human Platelets. Throm Haemostas 51(1): 32-36, Stuttgart, 1982) Platelet activation and release is implicated in the pathophysiology of such cardiovascular disorders as atherosclerosis; (Gross, R., and L. Harber. Hyperlipidemia and atherosclerosis. Science 193: 1084, 1976); thrombosis, (Hornstra, G. Dietary Fats and Arterial Thrombosis: Effects and Mechanism of

in additional application of the omega 3 fatty acid pathway lies in the physiological activities of their cellular products. EPA has been shown to lower platelet activity. (Hilme, S., J.H. Gross, H. Crane, and A. Morley. The Effect of Albumin Bound Polyunsaturated Fatty Acids on human Platelets. Throm Haemostas 51(1): 32-36, Stuttgart, 1982) Platelet activation and release is implicated in the pathophysiology of such cardiovascular disorders as atherosclerosis; (Gross, R., and L. Harber. Hyperlipidemia and atherosclerosis. Science 193: 1084, 1976); thrombosis, (Hornstra, G. Dietary Fats and Arterial Thrombosis: Effects and Mechanism of

Action. *Prog Biochem Pharmacol* 14: 326-338, 1977); myocardial infarction. (Hay, C.R.M., A.P. Durber, and R. Saynor, Effect of Fish Oil on Platelet Kinetics in Patients with Ischemic Heart Disease, *Lancet* 1269-1272, June 5, 1982); and shock. (Lefer, A.M. Role of the Prostaglandin-Thromboxane System in Vascular Homeostasis During Shock. *Circ Shock* 6: 297-303, 1979)

Many short-term studies involving the daily administration of some marine products to apparently healthy human subjects have demonstrated similar findings to those reported for Greenland Eskimos. There is a mild bleeding defect (prolonged bleeding time) and platelet aggregation response to collagen, or ADP is markedly reduced. (Goodnight, S.J., W.C. Harris, and W.E. Connor. The Effects of Dietary Omega-3 Fatty Acids on Platelet Composition and Function in Man: A Prospective, Controlled Study. *Blood* 58(5): 800-805, 1981; Thurngren, H., and A. Gustafson. Effects of 11-week Increase in Dietary Eicosapentaenoic Acid on Bleeding Time, Lipids, and Platelet Aggregation. *Lancet*: 1190-1193, Nov 28, 1981) In nonhuman primates with advanced atherosclerosis and markedly shortened platelet survival times, the offering of a diet containing EPA resulted in the normalizing of platelet survival times. (Ward, H.V., and T.B. Clarkson. The Effect of a Menhaden Oil Containing Diet on Hemostatic and Lipid Parameters of Nonhuman Primates with Atherosclerosis. *Atherosclerosis* (in press))

In most normal subjects and patients who consume such diets, total serum cholesterol, very low density lipoprotein cholesterol, and triglycerides are significantly lowered. (Mortensen, J.Z., E.B. Schmidt, A.H. Nielsen, and J. Overberg. The Effect of W-6 and W-3 Polyunsaturated Fatty Acids on Hemostasis, Blood Lipids and Blood Pressure. *Thromb Haemostas* 50(2): 543-546, Stuttgart, 1983; Phillipson, B.E., D.W. Rothrock, W.E. Connor, W.C. Harris, and D.R. Illingworth. Reduction of Plasma Lipids, Lipoproteins, and Apoproteins by Dietary Fish Oils in Patients with

Hypertriglyceridemia. *N Engl J Med* 312(19): 1210-1216, 1985) High density lipoproteins (HDL) cholesterol concentrations may be elevated in some subjects. (Sanders, T.A.B., and M.C. Hochland. Comparison of the Influence on Plasma Lipids and Platelet Function of Supplements of Omega-3 and Omega-6 Polyunsaturated Fatty Acids. *Nutr J Nutr* 50: 521-529, 1983) This pattern of change would be one thought to be less atherogenic.

Studies with animals have shown that those fed diets containing EPA, as opposed to commercial chows, have significant lower infarct sizes when their coronary or carotid arteries are ligated. (Culp, G.A., W.E.H. Lands, G.R. Lucchesi, B. Pitt, and Ranson. The Effect of Dietary Supplementation of Fish Oil on Experimental Myocardial Infarction. *Prostaglandins* 20(6): 1-10, 1979; Illingworth, K.L., B. Culp, D. Madison, O.S. Randall, and J. Lands. The Protective effects of dietary fish oil on experimental infarction. *Prostaglandins & Med* 3: 257-260, 1979) The difference is thought to be due to a reduced oxygen demand on the part of the affected tissue. This would support the findings from studies with nonhuman primates whereby a diet containing EPA had a sparing effect upon the onset and extent of myocardial ischemia after isoproterenol stress tests. (Ward, H.V. Unpublished findings, Bowman Gray School of Medicine, Birmingham, AL) In studies with human subjects fed marine products, both blood pressure and blood pressure response to exercise, urine fell significantly. (Lorenz, R., U. Spengler, S. Richter, J. Born, and P.C. Weber. Platelet function, Thrombocyte formation and blood pressure control during supplementation of a western diet with cod liver oil. *Circulation* 67(3): 504-511, 1983)

Change in fatty acid composition of blood cell membranes and serum may explain some of the aforementioned physiological observations. With the ingestion of a marine diet, the omega 3 fatty acids increase markedly at the expense of the omega 6 fatty acids.

-12-

lower than that of LTB_4 . (Terano, T., J.A. Salmon, and S. Moncada. Biosynthesis and Biological Activity of Leukotriene B_5 . Prostaglandins 27(2): 217-232, 1983)

U.K. Patent Application GB 2 139 869A discloses an emulsion for intravenous use which contains a fatty acid containing 20-22 carbon atoms or an ester of the fatty acid, a vegetable oil, an emulsifier and water.

It is an object of this invention to provide a lipid emulsion for intravenous therapy and treatment of thrombotic disease. It is a further object of this invention to provide an emulsion which inhibits formation of certain prostaglandins. It is a further object of this invention to provide such an emulsion wherein the concentrations of free fatty acids are below toxic levels.

Other objects will become hereinafter.

SUMMARY

We have found that lipid emulsions of marine oils comprising high concentrations of omega-3 fatty acid esters and low concentrations of free fatty acids are therapeutic when administered intravenously for the treatment of thrombotic disease states.

Specifically, a lipid emulsion for parenteral use is provided comprising an emulsifier, water, and a marine oil comprising an omega-3 fatty acid ester, in which the concentration of free fatty acid in the emulsion is below about 5 meq/l. Preferably, the concentration of marine oil in the emulsion is between 5 and 50 wt/v.

Specifically, marine oil containing omega-3 fatty acid esters is predominantly made of acids of 12-26 carbon atoms each, for example, esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), typically as a mixture, although pure species may be

-11-

There may even be other benefits to fish products. Certain mice that die at an early age of autoimmune disease have been given prostaglandin E_1 (PGE_1) or menhaden oil diets and exhibited markedly longer lifespans and a virtual disappearance of immune mediated glomerulonephritis. (Kelley, V.E., A. Winkelstein, S. Isui, and F.J. Dixon. Prostaglandin E_1 inhibits T-Cell Proliferation and Renal Disease in MRL/l Mice. Clin Immunology & Immunopathology 21: 190-203, 1981; Prickett, J.D., D.R. Robinson, and A.D. Steinberg. Dietary Enrichment with the Polyunsaturated Fatty Acid Eicosapentaenoic Acid Prevents Proteinuria and Prolongs Survival in M20 X NZW F₁ Mice. J Clin Invest 66: 552-559, 1981) Fish oil was also found to be beneficial in a marine model of angiodysplasia. (Hayes, K.D., E. Cathcart, C.A. Leslie, and S.H. Meydani. Dietary Fish Oil Alters Prostaglandin Metabolism to Decrease Platelet Aggregation in Monkeys and Angiodysplasia in Mice. Proc of Conf on Omega-3 Fatty Acids. Reading, England: Reading University, 131-132, Jul 16-18, 1984).

The beneficial effects of fish oils in inflammatory disorders stem, at least in part, from the interaction of EPA and arachidonic acid with the enzyme lipoygenase in inflammatory cells (neutrophils and monocytes). In the presence of EPA, these cells produce less Leukotriene B_4 (a major component of inflammatory response) and small amounts of Leukotriene B_5 . (Lee, T.H., R.L. Hoover, J.D. Williams, et al. Effect of Dietary Enrichment with Eicosapentaenoic and Docosahexaenoic Acids on *in vitro* Neutrophil and Monocyte Leukotriene Generation and Neutrophil Function. In Engl J. Med 312(19): 1217-1224, 1985) LTB_5 is at least 30 times less potent than LTB_4 in causing aggregation, chemokinesis and degranulation of human neutrophils *in vitro*. The potency of LTB_5 in potentiating bradykinin-induced plasma exudation, which is probably attributable to its leukotactic activity, is at least 10 times

The amount of oil to be used in the emulsion will depend upon the dosage, the percentage of fatty acid esters in the oil, and the total lipid concentration of the emulsion. Therapeutic dosages will be dependent upon body weight and infusion duration. The omega-3 fatty acid ester content of the oil will also vary depending upon the oil source. Concentrations will range from 10 to 100% and preferably at least 30%. For fatty acid concentration of total lipid emulsion should be below 5 mg/l. Concentration of the marine oil in the emulsion will vary between 5 to 50%. Preferred concentrations are between 10 to 20%; concentrations of emulsifiers will vary accordingly.

Emulsifiers which are useful in this invention include egg yolk phosphatide, soybean phosphatide, egg yolk lecithin, soybean lecithin and other purified phospholipids. Concentrations of the emulsifiers are dependent upon the amount of oil in the emulsion. Concentrations may range from 0.1 to 6%. For each additional 10% increase in oil, emulsifier concentration will increase approximately 0.4 to 1.2%. Preferred concentrations are about 0.4 to 1.2% where volume of oil is between 10 to 20%.

Various osmotic agents may also be added to the emulsion. Examples of such osmotic agents include glycerin, glucose, sucrose, sorbitol, protein and sodium acid phosphates. The osmolality of this solution preferably ranges between 200 to 300 milliosmoles. The remainder of the emulsion comprises mostly water and other optional additives.

The lipid particles in the emulsion will have a diameter of less than about 0.75 μ m and preferably less than about 0.5 μ m. The emulsions will be sterile and ordinarily are packaged in glass or plastic containers. They can be made by known methods. For example, see U.S. Patent 3,169,036 and European Patent Application 0071995. The emulsions herein are packaged and stored in hermetically sealed containers for long and short-term storage.

used as well). Preferably, the ester of EPA may be present in the marine oil in a concentration of 10 to 100% by weight.

Typical esters of EPA, DHA, or other unsaturated acids of 12-26 carbons are the glyceryl esters of naturally occurring fats.

The emulsifier may be any physiologically appropriate emulsifier, being typically selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, purified soy lecithin, and other purified phospholipids. The emulsifier concentration may typically range from 0.2 to 1.5%, and preferably about 0.3 to 0.8% for optimum product stability and bioavailability of EPA and DHA.

The term "omega-3 fatty acid ester" is defined to mean that the particular fatty acid included in the ester has a double bond occurring at the third position from the methyl end of the fatty acid. Likewise, the term "omega-6" implies that the first double bond in the molecule of the fatty acid in question occurs at the sixth position from the methyl end.

Preferably the lipid emulsions of this invention are free of vegetable oils and acids derived therefrom.

20 DETAILED DESCRIPTION OF THE INVENTION

All percentages in this application refer to weight/volume unless otherwise noted.

The intravenous lipid emulsions of this invention comprise marine oil, an emulsifier, and water.

The marine oils to be used herein are those which are preferably highly purified. These oils have a high concentration of fatty acid esters relative to free fatty acids. Examples of such oils include:

- menhaden oil,
- salmon oil,
- sardine oil,
- and other fish oils from cold water ocean fish.

Example 1

In a suitable vessel, 1.0 to 2.0 Kg of marine oil containing 15-30% glycerol ester of eicosapentaenoic acid (EPA) and 15-25% glycerol ester of docosahexaenoic acid (DHA), 120g of purified egg phospholipids, 225g of glycerol, USP, (as an osmotic agent) and water for injection USP are mixed to produce an emulsion having a 2.25% glycerol concentration and a 10 to 20% marine oil concentration. This emulsion is then homogenized repeatedly at high pressure to produce an emulsion of mean particle diameter of less than 0.75 μ m. During the process, the pH of the emulsion is adjusted to a physiological range with sodium hydroxide. The final volume is adjusted, if necessary with water for injection, USP, to 10 liters, and the emulsion is filtered into glass containers and heat sterilized by the normal procedure.

Example 11

A 10% lipid emulsion of the type of Example 1 was administered, via a cephalic vein intravenously, to each of 6 dogs, continuously over an 8 hour period, at a rate of 40 mg EPA/hr (2.5 ml/kg/hr). Each of the same 6 dogs received similar 8 hour infusions of Liposyn 10% Safflower oil lipid emulsion (Abbott Laboratories, North Chicago) and physiological saline (Travenol) in equivalent volumes to those administered for the Example 1 lipid emulsion (2.5 ml/kg/hr). There was a 21 day washout period between each infusion to the same dog. The order of treatments was randomized.

The Example 1 lipid emulsion contained 10 gm marine oil per 100 ml emulsion, and 16.42 mg EPA per ml of emulsion. From the time of production until the time of infusion, the Example 1 lipid emulsion was stored at approximately 4°C. During the infusion, the emulsion stood at room temperature.

Citrated whole blood samples were drawn from each dog at the following times: pre-infusion, and 2, 4, 6, 8, 10, 24, and 48 hours following the start of infusion. Assays completed with these blood samples included whole blood platelet aggregation to adenine-5-diphosphate (ADP) and collagen, prothrombin time, and activated partial thromboplastin time. Whole blood platelet counts were also measured at the above listed time periods, using whole blood collected into EDTA.

After the administration of the Example 1 lipid emulsion, dog platelets challenged with 8 μ M adenine-5-diphosphate (ADP) were inhibited 80%, 20.0% and 21% at 2, 24, and 48 hours after beginning infusion, respectively, when compared to pre-infusion responses. When these same platelets were challenged with 2 μ g/ml of acid soluble collagen, they were inhibited 72.9%, 25.8% and 20% at 2, 24, and 48 hours after beginning infusion, respectively.

When compared to pre-infusion responses, after the administration of Liposyn, dog platelet responses to both ADP and collagen were at or above (hyperactive) pre-infusion values at both 24 and 48 hours after beginning infusion. Platelet counts were unaltered by the infusion of the Example 1 lipid emulsion, Liposyn, or saline.

A cuticle bleeding time test was used in this dog study. This is an "open bleed" assessment of hemostatic capacity in which a toenail is severed in a manner sufficient to transect the vascular supply to that nail. The test measures the length of time required to cease bleeding. These tests were completed on each dog pre-infusion, and at 8 and 24 hours after beginning infusion.

Cuticle bleeding times of dogs receiving the Example 1 lipid emulsion were increased 150% and 152% above pre-infusion values at the 8 and 24 hour time periods, respectively. These increases were consistent with the inhibition of platelet function. Dogs receiving Liposyn had bleeding times decrease 14% and 22% below pre-infusion values at the 8 and 24 hours time periods.

-17-

respectively. These decreases were consistent with the platelet aggregation responses at the same time periods.

Blood coagulation tests revealed significant prolongations of both prothrombin times and activated partial thromboplastin times with blood samples collected from dogs receiving the Example 1 lipid emulsion. These changes were not seen with the infusion of saline or Liposyn.

Example III

A 10% lipid emulsion made as in Example I was administered, via a saphenous vein intravenously, to each of 6 African Green Monkeys, continuously over a six hour period, at a rate of 125mg EPA/kg/hr (5 ml/kg/hr). Each of the same six monkeys received similar six hour infusions of 10% lipid emulsion containing soybean oil (TRAVAMULSION®; Travenol Laboratories, Inc.) in equivalent volumes to those administered for the EPA lipid emulsion (5ml/kg/hr). There was a twenty-one day washout period between each infusion in the same monkey.

The Example 1 lipid emulsion contained 10 gm of marine oil per 100 ml emulsion, and 22 mg EPA/ml of emulsion. From the time of production until the time of infusion, the Example 1 lipid emulsion was stored at approximately 4°C. During the infusion, the emulsion stood at room temperature.

Citrated whole blood samples were drawn from each monkey pre-infusion, and at 6, 12, and 24 hours after beginning infusion. These samples were used to measure whole blood platelet aggregation to acid soluble collagen, and thromboxane B₂ release by platelets after platelet aggregation to collagen. Whole blood platelet counts were also measured at the above-listed time periods, using whole blood collected into EDTA.

Platelet counts remained unchanged for both treatments. The Example 1 lipid emulsion and TRAVAMULSION® lipid emulsion were

-18-

comparable in effect 6 hours after beginning infusion, when comparing platelet aggregation responses and thromboxane B₂ release values. EPA lipid emulsion was significantly more effective than TRAVAMULSION® lipid emulsion in reducing platelet function at both 12 and 24 hours after beginning infusion. The following is a summary of those responses:

Percent of Pre-Infusion African Green Monkey Platelet Function After Intravenous Lipid Emulsion

	Collagen	Hours after Beginning Infusion	EPA Lipid Emulsion Platelet Aggregation	EPA Lipid Emulsion Thromboxane Release	TRAVAMULSION® Platelet Thromboxane	
					aggregation	release
10	1 µg/ml Collagen	24	22.51	45.75	60.95	50.71
			14.5	22.8	77.4	57.1
			25.1	40.2	109.6	95.9
15	2 µg/ml Collagen	6	51.4	51.7	26.5	40.3
		12	30.5	30.6	108.3	59.0
		24	45.0	46.1	123.2	98.0

CLAIMS

We claim:

1. A lipid emulsion for parenteral use comprising an emulsifier, water and a marine oil comprising at least one omega 3 fatty acid ester wherein the concentration of free fatty acid in the emulsion is below about 5 meq/l.
2. The emulsion of Claim 1 wherein the concentration of marine oil is between about 5% to about 50%.
3. The emulsion of Claim 2 wherein the marine oil contains at least 30% by weight of a combination of esters of eicosapentaenoic acid and docosahexaenoic acid.
4. The emulsion of Claim 2 wherein the concentration of the ester of eicosapentaenoic acid in the marine oil is between about 10% to about 100%.
5. The emulsion of Claim 1 wherein the emulsifier is selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, purified soy lecithin and other purified phospholipids.
6. The emulsion of Claim 1 wherein the emulsifier concentration is either 1.2%, 0.6% or 0.4%, the latter two being the most effective in producing rapid bioavailability of eicosapentaenoic acid and docosahexaenoic acid.
7. The emulsion of Claim 1 further comprising an osmotic agent.
8. The emulsion of Claim 6 wherein the osmotic agent is selected from the group containing glycerin, glucose and sucrose, sorbitol, physiologically acceptable sodium phosphate.
9. The emulsion of Claim 1 in which essentially all lipid particles present have a diameter of less than 0.5 microns.
10. The emulsion of Claim 1 having an osmolarity of 280 to 300 milliosmoles.

11. A lipid emulsion for parenteral use comprising from 0.2 to 1.5% of an emulsifier selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, and purified soy lecithin, from 6 to 50% of a marine oil comprising at least 30% of omega-3 fatty acid esters of glycerol, and water, essentially all lipid particles in the emulsion having a diameter of less than 0.75 microns.
12. The lipid emulsion of Claim 11 in which the marine oil contains at least 30% by weight of a combination of glycerol esters of eicosapentaenoic acid and docosahexaenoic acid.
13. The lipid emulsion of Claim 12 in which the concentration of marine oil present is from 10 to 20%.
14. The lipid emulsion of Claim 13 in which an osmotic agent is present selected from the group consisting of glycerin, glucose, sorbitol, sorbitol, physiologically acceptable proteins, and sodium acid phosphate.
15. The lipid emulsion of Claim 14 in which sufficient osmotic agent is present to provide an osmolarity of 280 to 300 milliosmoles.
16. The lipid emulsion of Claim 15 in which less than 5 meq/l of free fatty acids are present.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US86/02066

<p>I. CLASSIFICATION OF SUBJECT MATTER (In several classification symbols 8801, indicate any: According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4): A61K 35/12, 31/685, 31/20 U.S. CL: 424/95, 514/77, 78, 560, 943</p>	
<p>II. FIELD SEARCHED</p>	
Classification System	Minimum Documentation Searched
U.S.	424/95; 514/77, 78, 560, 943
<p>Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Field Searched</p>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of Document, in which Indication, where appropriate, of the inventor's name	Relevant to Claim No. 1
Y	U.S.A. 4,513,008 (REVICI ET AL.), 23 April 1985 see col. 7, lines 20-26 and the claims	1-16
A	Journal of Clinical Investigation, Volume 73, issued January 1984, M. Neuringer et al., "Dietary Omega-3 Fatty Acid Deficiency", see pages 272-276.	1-16
A	The Lancet, issued 5 June 1982, C.R. Hay et al., "Effect of Fish oil on Platelet Kinetics", see pages 1269-1272.	1-16
A	Prostaglandins, Volume 27, No. 2, issued February 1984, T. Terano et al., "Biosynthesis and Biological Activity of Leukotriene B ₅ ", see pages 217-232.	1-16

- * Special categories of cited documents:
 - "A" document defining the general state of the art which is not considered to be of particular relevance
 - "X" document published on or after the international filing date
 - "Y" document which may throw doubt on priority (limit) or which is cited to establish the priority of another document or referring to an oral disclosure, use, exhibition or other means
 - "W" document published prior to the international filing date but later than the priority date claimed
- * "I" later document published after the international filing date or during prosecution of the application, which is cited to illustrate the state of the art or to demonstrate the principle of theory underlying the invention
- * "X" document of particular relevance: the claimed invention claimed be considered novel or cannot be considered to involve an inventive step
- * "Y" document of particular relevance: the claimed invention claimed be considered to involve an inventive step when the document is combined with one or more of the other cited documents, such combination being grounds for a person skilled in the art to arrive at the claimed invention
- * "W" document member of the same patent family

<p>IV. CERTIFICATION</p>	
<p>Date of the Actual Completion of the International Search</p>	<p>Date of Mailing of this International Search Report</p>
<p>9 December 1986</p>	<p>22 DEC 1986</p>
<p>Signature of the International Searching Authority</p>	<p>Signature of the Applicant</p>
<p>19A/US</p>	<p>John N. Rollins</p>

International Application No. PCT/US86/02066

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	American Heart Journal, Volume 80, No. 5, issued November 1970, L.A. Soloff, "Arhythmias Following Infusion of Fatty Acids, see pages 671-674,	1-16
A	New England Journal of Medicine Volume 112, No. 12, issued May 1985, "Effect of Fish Oil on Leukocytes", see pages 1217-1224.	1-16

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 11(2) (a) for the following reasons:

- ☐ Claim numbers: Because they relate to subject matter which is not required to be searched by this Authority, namely:

- ☐ Claim numbers: Because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out in a satisfactory manner.

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

- ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
- ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers: these claims of the international application for which fees were paid, specifically claims:
- ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims. It is covered by claim numbers:

- ☐ As all searchable claims could be searched without payment of an additional fee, the International Searching Authority also made payment of any additional fee.

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Atherosclerosis, Volume 57, issued 1985, M.V. Ward et al. "The Effect of a Menhaden Oil-Containing Diet on Fatty Acid and Lipid Parameters of Non human Primates with Atherosclerosis, see pages 325-335	1-16
A	Prostaglandins and Medicine, Volume 3, issued 1979, M. Black et al., The Protective Effects of Dietary Fish Oil on focal Cerebral Infarction", see pages 257-286	1-16
A	The American Journal of Clinical Nutrition, Volume 41, issued May 1985, R. Cotter et al; "Comparison of the Elimination of 10 and 20% TRAVAMULSION TM Lipid Emulsion From The Blood of Beagle Dogs. see pages 994-1001.	1-16
A	Journal of Parenteral and Enteral Nutrition, Volume 8, No. 2, issued 1984, R. Cotter et al., "Comparison of the Elimination and Metabolism of 10% Travamulsion and 10% Intralipid Lipid Emulsion in the Dog". see pages 140-145	1-16
A	Prostaglandins, Volume 20, No. 6, issued December 1980, B. Culp et al., "The Effect of Dietary Supplement of Fish Oil on Experimental Myocardial Infarction" see pages 1021-1031.	1-16
A	Archives of Internal Medicine, Volume 107 issued April 1961, C. Alexander et al., "Fat Infusions", see pages 514-528	1-16
A	American Journal of Clinical Nutrition, Volume 16, issued January 1965, H. Meng et al., "Effects of Multiple Infusions of a Fat Emulsion on Blood Coagulation, Liver Function and Urinary Excretion of Steroids in Schizophrenic Patients", see pages 156-164	1-16

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Journal of Parenteral and Enteral Nutrition, Volume 7, No. 3, issued 1983, R. Cotter et al., "Determination of the Kinetics of the Elimination of Lipid Emulsion Administered Intravenously to Dogs", see pages 240-250	1-16
A	Archives of Surgery, Volume 111, issued December 1976, R. Bellin et al., "Fat Overload with a 10% Soybean Oil Emulsion", see pages 1391-1393.	1-16

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.